Different expression of alternative lengthening of telomere (ALT)-associated proteins/mRNAs in osteosarcoma cell lines

Oncology Letters

Volumn 2, Issue 6, 2011, Pages 1327-1332

  Zhang, Yi ^a   Cai, Lin ^a   Wei, Ren Xiong ^a   Hu, Hao ^a   Jin, Wei ^a   Zhu, Xiao Bin ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Alternative lengthening of telomeres; Osteosarcoma; Telomerase; Telomere maintenance mechanism

Indexed keywords

ALTERNATIVE LENGTHENING OF TELOMERE ASSOCIATED PROTEIN; MESSENGER RNA; MRE11 PROTEIN; NUCLEIC ACID BINDING PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RAD52 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; TELOMERE;

EID: 80052692748     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.403     Document Type: Article

References (45)

1. Arndt CA and Crist WM: Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 341: 342-352, 1999.
2. Endo-Munoz L, Cumming A, Sommerville S, Dickinson I and Saunders NA: Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone. Br J Cancer 103: 73-81, 2010.
3. Tabori U and Dome JS. Telomere biology of pediatric cancer. Cancer Invest 25: 197-208, 2007.
4. Brachner A, Sasgary S, Pirker C, et al: Telomerase-and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT. Cancer Res 66: 3584-3592, 2006.
5. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods 25: 402-408, 2001.
6. Smith CC, Aylott MC, Fisher KJ, Lynch AM and Gooderham NJ: DNA damage responses after exposure to DNA-based products. J Gene Med 8: 175-85, 2006.
7. Smogorzewska A, Karlseder J, Holtgreve-Grez H, Jauch A and de Lange T: DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 and G2. Curr Biol 12: 1635-1644, 2002.
8. D'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al: A DNA damage checkpoint response in telomere-initiated senescence. Nature 426: 194-198, 2003.
9. Bakkenist CJ, Drissi R, Wu J, Kastan MB and Dome JS: Disappearance of the telomere dysfunction-induced stress response in fully senescent cells. Cancer Res 64: 3748-3752, 2004.
10. Shay JW and Wright WE: Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol 1: 72-76, 2000.
11. Makarov VL, Hirose Y and Langmore JP: Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 88: 657-666, 1997.
12. Palm W and de Lange T: How shelterin protects mammalian telomeres. Annu Rev Genet 42: 301-334, 2008.
13. Artandi SE and DePinho RA: Telomeres and telomerase in cancer. Carcinogenesis 31: 9-18, 2010.
14. Weinrich SL, Pruzan R, Ma L, et al: Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 17: 498-502, 1997.
15. Henson JD, Neumann AA, Yeager TR and Reddel RR: Alternative lengthening of telomeres in mammalian cells. Oncogene 21: 598-610, 2002.
16. Xu ZX, Zou WX, Lin P and Chang KS: A role for PML3 in centrosome duplication and genome stability. Mol Cell 17: 721-732, 2005.
17. Nakayama J, Tahara H, Tahara E, et al: Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 18: 65-68, 1998.
18. Blasco MA, Funk W, Villeponteau B and Greider CW: Functional characterization and developmental regulation of mouse telomerase RNA. Science 269: 1267-1270, 1995.
19. Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S and Greider CW: Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 56: 645-650, 1996.
20. Beattie TL, Zhou W, Robinson MO and Harrington L: Polymerization defects within human telomerase are distinct from telomerase RNA and TEP1 binding. Mol Biol Cell 11: 3329-3340, 2000.
21. Kickhoefer VA, Stephen AG, Harrington L, Robinson MO and Rome LH: Vaults and telomerase share a common subunit, TEP1. J Biol Chem 274: 32712-32717, 1999.
22. Kickhoefer VA, Liu Y, Kong LB, et al: The telomerase/vault-associated protein TEP1 is required for vault RNA stability and its association with the vault particle. J Cell Biol 152: 157-164, 2001.
23. Liu Y, Snow BE, Hande MP, et al: Telomerase-associated protein TEP1 is not essential for telomerase activity or telomere length maintenance in vivo. Mol Cell Biol 20: 8178-8184, 2000.
24. Ulaner GA, Huang HY, Otero J, et al: Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 63: 1759-1763, 2003.
25. Terasaki T, Kyo S and Takakura M: Analysis of telomerase activity and telomere length in bone and soft tissue tumors. Oncol Rep 11: 1307-1311, 2004.
26. Fujiwara-Akita H, Maesawa C, Honda T, Kobayashi S and Masuda T: Expression of human telomerase reverse transcriptase splice variants is well correlated with low telomerase activity in osteosarcoma cell lines. Int J Oncol 26: 1009-1016, 2005.
27. Sotillo-Piñeiro E, Sierrasesúmaga L and Patiñno-García A: Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients. Pediatr Res 55: 231-235, 2004.
28. Yu ST, Chen L, Wang HJ, Tang XD, Fang DC and Yang SM: hTERT promotes the invasion of telomerase-negative tumor cells in vitro. Int J Oncol 35: 329-336, 2009.
29. Jegou T, Chung I, Heuvelman G, et al: Dynamics of telomeres and promyelocytic leukemia nuclear bodies in a telomerase-negative human cell line. Mol Biol Cell 20: 2070-2082, 2009.
30. Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB and Dome JS: Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol 22: 3790-3797, 2004.
31. Herbert BS, Gellert GC, Hochreiter A, et al: Lipid modification of GRN163, an N3'→P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24: 5262-5268, 2005.
32. Pascolo E, Wenz C, Lingner J, et al: Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 277: 15566-15572, 2002.
33. Perrem K, Colgin LM, Neumann AA, Yeager TR and Reddel RR: Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol 21: 3862-3875, 2001.
34. Costa A, Daidone MG, Daprai L, et al: Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 66: 8918-8924, 2006.
35. Bhattacharyya S, Sandy A and Groden J: Unwinding protein complexes in ALTernative telomere maintenance. J Cell Biochem 109: 7-15, 2010.
36. Mankouri HW and Hickson ID: The RecQ helicase-topoisomerase III-Rmi1 complex: a DNA structure-specific 'dissolvasome'? Trends Biochem Sci 32: 538-546, 2007.
37. Raynard S, Zhao W, Bussen W, et al: Functional role of BLAP75 in BLM-topoisomerase IIIalpha-dependent holliday junction processing. J Biol Chem 283: 15701-15708, 2008.
38. Jiang WQ, Zhong ZH, Henson JD, Neumann AA, Chang AC and Reddel RR: Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 complex. Mol Cell Biol 25: 2708-2721, 2005.
39. Sugawara N, Wang X and Haber JE: In vivo roles of Rad52, Rad54, and Rad55 proteins in Rad51-mediated recombination. Mol Cell 2: 209-219, 2003.
40. Miyazaki T, Bressan DA, Shinohara M, Haber JE and Shinohara A: In vivo assembly and disassembly of Rad51 and Rad52 complexes during double-strand break repair. EMBO J 3: 939-949, 2004.
41. Saharia A and Stewart SA: FEN1 contributes to telomere stability in ALT-positive tumor cells. Oncogene 28: 1162-1167, 2009.
42. Zeng S, Xiang T, Pandita TK, et al: Telomere recombination requires the MUS81 endonuclease. Nat Cell Biol 11: 616-623, 2009.
43. Fan Q, Zhang F, Barrett B, Ren K and Andreassen PR: A role for monoubiquitinated FANCD2 at telomeres in ALT cells. Nucleic Acids Res 37: 1740-1754, 2009.
44. Wu G, Jiang X, Lee WH and Chen PL: Assembly of functional ALT-associated promyelocytic leukemia bodies requires Nijmegen Breakage Syndrome 1. Cancer Res 63: 2589-2595, 2003.
45. Henson JD, Cao Y, Huschtscha LI, et al: DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol 27: 1181-1185, 2009.